Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are we making progress in antifungal therapy?

P Martino1, C Girmenia

  • 1Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy.

Current Opinion in Oncology
|July 1, 1997
PubMed
Summary

Treatment for invasive fungal infections in cancer patients remains challenging. Recent advances focus on new antifungal drugs and therapies to improve outcomes for these vulnerable patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Construction and validation of a test for verbal auditory screening of cognitive alterations (CAVAC)].

Revista de neurologia·2024
Same author

[Three tasks for the exploration of verbal fluency: evidence of test-retest reliability in Argentine adults].

Revista de neurologia·2022
Same author

[Cognitive Reserve Questionnaire: psychometric analysis from the item response theory].

Revista de neurologia·2022
Same author

[Montreal Cognitive Assessment (MoCA): normative data for Rosario metropolitan area population, Argentina].

Revista de neurologia·2022
Same author

COVID-19 in the South African Medical Journal.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2022
Same author

[Cognitive reserve questionnaire: the psychometric properties in an Argentinian population].

Revista de neurologia·2021

Area of Science:

  • Mycology
  • Oncology
  • Infectious Diseases

Background:

  • Invasive mycoses in cancer patients have seen limited therapeutic progress.
  • Amphotericin B deoxycholate, despite toxicity, remains a primary treatment for severe fungal infections.
  • Newer azoles like fluconazole and itraconazole offer improvements but have limitations, including resistance and absorption issues.

Purpose of the Study:

  • To review recent advancements in treating fungal infections in cancer patients.
  • To highlight challenges in current antifungal therapy for immunocompromised individuals.
  • To discuss emerging strategies beyond traditional antifungal agents.

Main Methods:

  • Review of recent laboratory and clinical research.
  • Analysis of new antifungal formulations and drug classes.
  • Exploration of immunomodulation in conjunction with antifungal therapy.

Main Results:

  • Development of novel antifungal formulations and new drug classes is ongoing.
  • Emergence of antifungal resistance necessitates broader-spectrum agents.
  • Combination therapy, including immunomodulation, shows promise.

Conclusions:

  • Significant unmet needs persist in managing invasive mycoses in cancer patients.
  • Advances in antifungal drug development are crucial for improving patient survival.
  • Future strategies involve novel agents, improved formulations, and combination therapies.

Related Experiment Videos